Paper39335124
Therapeutic Opportunities for Biomarkers in Metastatic Spine Tumors.
Schroeder C and 9 others. Cancers (Basel), 2024. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Therapeutic Opportunities for Biomarkers in Metastatic Spine Tumors. Papers, record 39335124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39335124
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References117
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27551478 | FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. | Cell Death Discov | 2015 | https://conductscience.org/library/papers/27551478 | PubMed |
| 2 | 31900168 | Tumor microenvironment differences between primary tumor and brain metastases. | J Transl Med | 2020 | https://conductscience.org/library/papers/31900168 | PubMed |
| 3 | 26977847 | The evolving role of immunotherapy in prostate cancer. | Curr Opin Oncol | 2016 | https://conductscience.org/library/papers/26977847 | PubMed |
| 4 | 26122181 | ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. | Nat Rev Clin Oncol | 2015 | https://conductscience.org/library/papers/26122181 | PubMed |
| 5 | 31137764 | Prostate Cancer and Bone Metastases: The Underlying Mechanisms. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31137764 | PubMed |
| 6 | 24239464 | Biomarkers of renal cell carcinoma. | Urol Oncol | 2014 | https://conductscience.org/library/papers/24239464 | PubMed |
| 7 | 25504108 | Downregulation of CXCR4 by SDF-KDEL in SBC-5 cells inhibits their migration in vitro and organ metastasis in vivo. | Int J Mol Med | 2015 | https://conductscience.org/library/papers/25504108 | PubMed |
| 8 | 2997622 | L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. | Nature | 1985 | https://conductscience.org/library/papers/2997622 | PubMed |
| 9 | 23401436 | ALK in lung cancer: past, present, and future. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23401436 | PubMed |
| 10 | 23912959 | CX3CL1 expression is associated with poor outcome in breast cancer patients. | Breast Cancer Res Treat | 2013 | https://conductscience.org/library/papers/23912959 | PubMed |
| 11 | 35783639 | A Novel Overall Survival Prediction Signature Based on Comprehensive Research in Prostate Cancer Bone Metastases. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/35783639 | PubMed |
| 12 | 21678053 | Down-regulation of β3-integrin inhibits bone metastasis of small cell lung cancer. | Mol Biol Rep | 2012 | https://conductscience.org/library/papers/21678053 | PubMed |
| 13 | 24482365 | PTEN is a potent suppressor of small cell lung cancer. | Mol Cancer Res | 2014 | https://conductscience.org/library/papers/24482365 | PubMed |
| 14 | 30345906 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30345906 | PubMed |
| 15 | 37690663 | Metabolic signature biomarkers for predicting the recurrence of urological cancers. | Clin Chim Acta | 2023 | https://conductscience.org/library/papers/37690663 | PubMed |
| 16 | 22695242 | The role of genetic markers in the management of prostate cancer. | Eur Urol | 2012 | https://conductscience.org/library/papers/22695242 | PubMed |
| 17 | 31091374 | Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31091374 | PubMed |
| 18 | 34098744 | KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. | Future Oncol | 2021 | https://conductscience.org/library/papers/34098744 | PubMed |
| 19 | 25220842 | Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. | Int J Cancer | 2015 | https://conductscience.org/library/papers/25220842 | PubMed |
| 20 | 32657049 | Genetic profile of non-small cell lung cancer (NSCLC): A hospital-based survey in Jinhua. | Mol Genet Genomic Med | 2020 | https://conductscience.org/library/papers/32657049 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41744820 | CHI3L1 Expression in Chordoma: Implications for Immunotherapeutic Intervention. | Cells | 2026 | https://conductscience.org/library/papers/41744820 | PubMed |
| 40868304 | Artificial Intelligence for Non-Invasive Prediction of Molecular Signatures in Spinal Metastases: A Systematic Review. | Bioengineering (Basel) | 2025 | https://conductscience.org/library/papers/40868304 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39335124
GET https://conductscience.org/api/papers/v1/39335124/references?page=2